33 Stocks Moving In Friday’s Mid-Day Session
Gainers
Revlon, Inc. (NYSE: REV) gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.
U.S. Markets Open Higher; Dow Rises Around 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Friday.
82 Biggest Movers From Yesterday
Gainers
Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday.
Mid-Afternoon Market Update: Gold Down Over 2%; Electric Last Mile Solutions Shares Plummet
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping by more than 3% on Monday.
Analysts Consider CRISPR Therapeutics’ Blood Disorder Trial Data Encouraging, Impressive
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.
70 Stocks Moving In Monday’s Mid-Day Session
Gainers
Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric low-grade glioma showed an overall response rate of 64%.
FDA Advisory Committee Backs Bluebird Bio’s Blood Disorder Gene Therapy
The FDA’s Advisory Committee has unanimously backed Bluebird bio Inc’s (NASDAQ:BLUE) gene therapy for a rare blood disorder. The panel of…
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day volume over the last 100 days. The company's market cap stands at $437.2 million.
bluebird bio Announces FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy For People With beta-thalassemia Who Require Regular Red Blood Cell Transfusions
Current standard of care relies on regular red blood cell transfusions and iron management that carry the risk of progressive multi-organ damage and increased risk of morbidity and mortality
If approved, beti-cel will